BRPI0917224A2 - formas cristalinas de um derivado de piridina - Google Patents

formas cristalinas de um derivado de piridina

Info

Publication number
BRPI0917224A2
BRPI0917224A2 BRPI0917224A BRPI0917224A BRPI0917224A2 BR PI0917224 A2 BRPI0917224 A2 BR PI0917224A2 BR PI0917224 A BRPI0917224 A BR PI0917224A BR PI0917224 A BRPI0917224 A BR PI0917224A BR PI0917224 A2 BRPI0917224 A2 BR PI0917224A2
Authority
BR
Brazil
Prior art keywords
crystalline forms
pyridine derivative
pyridine
derivative
crystalline
Prior art date
Application number
BRPI0917224A
Other languages
English (en)
Inventor
Clare Louise Anderton
David Clapham
Ronnie Maxwell
Original Assignee
Glaxosmithkline Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Llc filed Critical Glaxosmithkline Llc
Publication of BRPI0917224A2 publication Critical patent/BRPI0917224A2/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53831,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
BRPI0917224A 2008-08-05 2009-08-04 formas cristalinas de um derivado de piridina BRPI0917224A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0814340.6A GB0814340D0 (en) 2008-08-05 2008-08-05 Anhydrous crystol form fo a pyridine derivative
PCT/EP2009/060089 WO2010015626A1 (en) 2008-08-05 2009-08-04 Crystalline forms of a pyridine derivative

Publications (1)

Publication Number Publication Date
BRPI0917224A2 true BRPI0917224A2 (pt) 2015-11-24

Family

ID=39767571

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0917224A BRPI0917224A2 (pt) 2008-08-05 2009-08-04 formas cristalinas de um derivado de piridina

Country Status (14)

Country Link
US (1) US8093242B2 (pt)
EP (1) EP2321324A1 (pt)
JP (1) JP2011529942A (pt)
KR (1) KR20110052686A (pt)
CN (1) CN102171219A (pt)
AU (1) AU2009279135B2 (pt)
BR (1) BRPI0917224A2 (pt)
CA (1) CA2733235A1 (pt)
EA (1) EA201170300A1 (pt)
GB (1) GB0814340D0 (pt)
IL (1) IL210777A0 (pt)
MX (1) MX2011001414A (pt)
WO (1) WO2010015626A1 (pt)
ZA (1) ZA201100426B (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8796269B2 (en) * 2009-08-27 2014-08-05 Nerre Therapeutics Limited Crystalline 2-(3,5-Bis(trifluoromethyl)phenyl)-N-(4-(4-fluoro-2-methylphenyl)-6-((7S,9aS)-7-(hydroxymethyl)hexahydropyrazino[2,1-c][1,4]oxazin-8(1H)-yl)pyridin-3-yl)-N,2-dimethyl-propanamide of the formula (I), their use in therapy, and process for the preparation of the same
BR112017024852B1 (pt) * 2015-05-18 2023-10-31 KaNDy Therapeutics Limited Usos de um composto antagonista do receptor nk-1/nk-3 duplo e de uma composição farmacêutica compreendendo dito composto para o tratamento de sintomas vasomotores associados com menopausa
SG11202008226YA (en) 2018-03-14 2020-09-29 Kandy Therapeutics Ltd Novel pharmaceutical formulation comprising dual nk-1/nk-3 receptor antagonists

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69728883T2 (de) 1996-07-17 2005-04-07 Merck & Co., Inc. Änderung des zirkadischen rhythmus mit nicht-peptidischen neurokinin-1 rezeptor antagonisten
EP1035115B1 (en) 1999-02-24 2004-09-29 F. Hoffmann-La Roche Ag 4-Phenylpyridine derivatives and their use as NK-1 receptor antagonists
AU7788500A (en) 1999-10-25 2001-05-08 Janssen Pharmaceutica N.V. Use of substance p antagonists for influencing the circadian timing system
GB0203022D0 (en) 2002-02-08 2002-03-27 Glaxo Group Ltd Chemical compounds
GB0203020D0 (en) 2002-02-08 2002-03-27 Glaxo Group Ltd Chemical compounds
TW200403058A (en) * 2002-04-19 2004-03-01 Bristol Myers Squibb Co Heterocyclo inhibitors of potassium channel function
JP4490421B2 (ja) * 2003-07-03 2010-06-23 エフ.ホフマン−ラ ロシュ アーゲー 統合失調症を処置するデュアルnk1/nk3アンタゴニスト
AR058805A1 (es) * 2005-09-09 2008-02-27 Smithkline Beecham Corp Derivados biciclicos de piridina utiles como agentes antipsicoticos

Also Published As

Publication number Publication date
EP2321324A1 (en) 2011-05-18
JP2011529942A (ja) 2011-12-15
AU2009279135A1 (en) 2010-02-11
CA2733235A1 (en) 2010-02-11
WO2010015626A1 (en) 2010-02-11
KR20110052686A (ko) 2011-05-18
US20110136798A1 (en) 2011-06-09
MX2011001414A (es) 2011-04-04
AU2009279135B2 (en) 2012-09-13
ZA201100426B (en) 2012-03-28
US8093242B2 (en) 2012-01-10
CN102171219A (zh) 2011-08-31
IL210777A0 (en) 2011-03-31
GB0814340D0 (en) 2008-09-10
EA201170300A1 (ru) 2011-08-30

Similar Documents

Publication Publication Date Title
DK2262793T3 (da) Krystallinske former af nilotinib-hci
BRPI0915714A2 (pt) forma cristalina de posaconazol
DK2300465T3 (da) Imidazopyridinderivater som hæmmere af receptortyrosinkinaser
BRPI1013246A2 (pt) derivados de benzofuralina
BR112012002828A2 (pt) derivados de 5-fluorpirimidinona
DK2308877T3 (da) Imidazopyridin-2-on-derivater
ECSP12011999A (es) Derivados benzamida sustituidos
BRPI0913832A2 (pt) derivados de pirrolopiridinilpirimidin-2-ilamina
BRPI0915064A2 (pt) derivados de qunoxalinadiona
BRPI1013844A2 (pt) derivados de piridina-isoxazol
DK2275414T3 (da) Cyclopentylacrylamidderivat
BRPI1014454A2 (pt) derivados de isoxazol-pirazol
ATE545635T1 (de) Substituierte n-oxidpyrazinderivate
BRPI0908512A2 (pt) elemento tubular
BRPI0913234A2 (pt) derivados de tiazolilpiperidina
BRPI1007201A2 (pt) elemento de construção
BRPI1011416A2 (pt) derivados de antraquinova novos
BR112012002810A2 (pt) derivados de n1-acil-5-fluoropirimidinona
ATE534634T1 (de) 2-phenyl-4-cyclopropyl-pyrimidinderivate
BRPI0922652A2 (pt) Derivados de quinazolinamida
BR112012003435A2 (pt) formas anidras de um derivado de píridina
BRPI0909425A2 (pt) derivado de hidroxiquinoxalinacarboxamida
CU23884B1 (es) Derivados de dibenzotiazepina
BRPI1007893A2 (pt) derivado de cianopirimidina
BRPI0917224A2 (pt) formas cristalinas de um derivado de piridina

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 5A, 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2384 DE 13-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.